It's not every day you hear of a new $33M going into spatial diagnostics - but it happened this week.
WAIV Diagnostics, Paris (former Owkin Dx) is now a spinout from Owkin and pulling in its own investors and funding.
https://wearewaiv.com/news/waiv-secures-33-million-to-scale-ai-precision-testing
See also a post from Meriem Sefta, WAIV CEO.
"We exist to catalyze precision medicine with clinical-grade, AI-powered tests designed to detect biomarkers, predict outcomes, and better understand treatment response in oncology."
###
It's a fit with the Bloodpac webinar and white paper, "it's not just DNA mutations anymore" - here.
https://www.discoveriesinhealthpolicy.com/2026/03/bloodpac-releases-webinar-and-white.html
